Kuhlen M, et al. – In order to assess neurotoxic side effects in children with refractory or relapsed T–cell malignancies treated with nelarabine based therapy, analysts performed this study. They did not find any differences between mono– and combination therapy concerning outcome and neuro–adverse effect (AE). As per observations, there was no link between the incidence of neuro–AE and concurrent intrathecal therapy or prior central nervous system irradiation.